In vitro combined effects of a triazene compound and interferon-beta on natural immunity against lymphoblastoid cells: Studies at effector and target cell level

L. Bonmassar, S. D'atri, M. Turriziani, A. Giuliani

Research output: Contribution to journalArticle

Abstract

It was shown that Dacarbazine and other triazene compounds render murine leukemias highly immunogenic and susceptible to natural immunity (NI). In addition a pilot clinical study revealed that Dacarbazine can be cytotoxic for bone marrow blasts in patients with acute non-lymphoblastic leukemias through a mechanism that could be, at least in part, of immunological origin. However triazenes depress antigen-dependent responses and NI, whereas interferons, including interferon-beta (IFN), antagonize drug-induced impairment of NI. Therefore the complex interaction between triazenes and IFN on NI effector (i.e. NK) lymphocytes and human target lymphoblastoid cells has been investigated. the results show that: (a) EFN increases NK activity and antagonizes the depressive effects of methyl-triazene-benzoic acid (MTBA, an in vitro active triazene compound) on the NK function; (b) a lymphoblastoid cell line exposed to multiple in vitro treatments with MTBA, shows increased growth rate, augmented chemoresistance to MTBA, and higher susceptibility to NI than parental cells; (c) as expected IFN pretreatment down-regulates the susceptibility of lymphoblastoid cells to NK effectors; (d) however a net "therapeutic gain" was found if the overall influence of MTBA + IFN on target and effector cells is considered.

Original languageEnglish
Pages (from-to)695-715
Number of pages21
JournalImmunopharmacology and Immunotoxicology
Volume16
Issue number4
DOIs
Publication statusPublished - 1994

Fingerprint

Triazenes
Interferon-beta
Innate Immunity
Dacarbazine
Benzoic Acid
Lymphocytes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Natural Killer Cells
Interferons
Bone
Leukemia
Down-Regulation
Bone Marrow
Cells
In Vitro Techniques
Antigens
Cell Line
1-4-(3-methyltriazeno)benzoic acid
Therapeutics
Growth

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

@article{cbd8cb4b4a5f474680bde385a585b364,
title = "In vitro combined effects of a triazene compound and interferon-beta on natural immunity against lymphoblastoid cells: Studies at effector and target cell level",
abstract = "It was shown that Dacarbazine and other triazene compounds render murine leukemias highly immunogenic and susceptible to natural immunity (NI). In addition a pilot clinical study revealed that Dacarbazine can be cytotoxic for bone marrow blasts in patients with acute non-lymphoblastic leukemias through a mechanism that could be, at least in part, of immunological origin. However triazenes depress antigen-dependent responses and NI, whereas interferons, including interferon-beta (IFN), antagonize drug-induced impairment of NI. Therefore the complex interaction between triazenes and IFN on NI effector (i.e. NK) lymphocytes and human target lymphoblastoid cells has been investigated. the results show that: (a) EFN increases NK activity and antagonizes the depressive effects of methyl-triazene-benzoic acid (MTBA, an in vitro active triazene compound) on the NK function; (b) a lymphoblastoid cell line exposed to multiple in vitro treatments with MTBA, shows increased growth rate, augmented chemoresistance to MTBA, and higher susceptibility to NI than parental cells; (c) as expected IFN pretreatment down-regulates the susceptibility of lymphoblastoid cells to NK effectors; (d) however a net {"}therapeutic gain{"} was found if the overall influence of MTBA + IFN on target and effector cells is considered.",
author = "L. Bonmassar and S. D'atri and M. Turriziani and A. Giuliani",
year = "1994",
doi = "10.3109/08923979409019746",
language = "English",
volume = "16",
pages = "695--715",
journal = "Immunopharmacology and Immunotoxicology",
issn = "0892-3973",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - In vitro combined effects of a triazene compound and interferon-beta on natural immunity against lymphoblastoid cells

T2 - Studies at effector and target cell level

AU - Bonmassar, L.

AU - D'atri, S.

AU - Turriziani, M.

AU - Giuliani, A.

PY - 1994

Y1 - 1994

N2 - It was shown that Dacarbazine and other triazene compounds render murine leukemias highly immunogenic and susceptible to natural immunity (NI). In addition a pilot clinical study revealed that Dacarbazine can be cytotoxic for bone marrow blasts in patients with acute non-lymphoblastic leukemias through a mechanism that could be, at least in part, of immunological origin. However triazenes depress antigen-dependent responses and NI, whereas interferons, including interferon-beta (IFN), antagonize drug-induced impairment of NI. Therefore the complex interaction between triazenes and IFN on NI effector (i.e. NK) lymphocytes and human target lymphoblastoid cells has been investigated. the results show that: (a) EFN increases NK activity and antagonizes the depressive effects of methyl-triazene-benzoic acid (MTBA, an in vitro active triazene compound) on the NK function; (b) a lymphoblastoid cell line exposed to multiple in vitro treatments with MTBA, shows increased growth rate, augmented chemoresistance to MTBA, and higher susceptibility to NI than parental cells; (c) as expected IFN pretreatment down-regulates the susceptibility of lymphoblastoid cells to NK effectors; (d) however a net "therapeutic gain" was found if the overall influence of MTBA + IFN on target and effector cells is considered.

AB - It was shown that Dacarbazine and other triazene compounds render murine leukemias highly immunogenic and susceptible to natural immunity (NI). In addition a pilot clinical study revealed that Dacarbazine can be cytotoxic for bone marrow blasts in patients with acute non-lymphoblastic leukemias through a mechanism that could be, at least in part, of immunological origin. However triazenes depress antigen-dependent responses and NI, whereas interferons, including interferon-beta (IFN), antagonize drug-induced impairment of NI. Therefore the complex interaction between triazenes and IFN on NI effector (i.e. NK) lymphocytes and human target lymphoblastoid cells has been investigated. the results show that: (a) EFN increases NK activity and antagonizes the depressive effects of methyl-triazene-benzoic acid (MTBA, an in vitro active triazene compound) on the NK function; (b) a lymphoblastoid cell line exposed to multiple in vitro treatments with MTBA, shows increased growth rate, augmented chemoresistance to MTBA, and higher susceptibility to NI than parental cells; (c) as expected IFN pretreatment down-regulates the susceptibility of lymphoblastoid cells to NK effectors; (d) however a net "therapeutic gain" was found if the overall influence of MTBA + IFN on target and effector cells is considered.

UR - http://www.scopus.com/inward/record.url?scp=0028073450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028073450&partnerID=8YFLogxK

U2 - 10.3109/08923979409019746

DO - 10.3109/08923979409019746

M3 - Article

C2 - 7876468

AN - SCOPUS:0028073450

VL - 16

SP - 695

EP - 715

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

SN - 0892-3973

IS - 4

ER -